Cellectar Biosciences, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Cellectar Biosciences, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($4.44M) | Nov 13, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($5.45M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($5.45M) | Aug 14, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($6.60M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($6.60M) | May 13, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($6.60M) | Nov 13, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($14.66M) | Nov 13, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($919.4K) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($919.4K) | Aug 14, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($26.64M) | Aug 14, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($26.64M) | Nov 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($26.64M) | May 13, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($17.52M) | Nov 18, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($10.18M) | Nov 18, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($10.18M) | Oct 29, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($7.19M) | Oct 29, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($7.19M) | Oct 29, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($7.19M) | Nov 18, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($7.81M) | Nov 13, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($7.44M) | Aug 14, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($4.85M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($6.04M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($6.40M) | May 13, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($13.33M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($13.70M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($12.00M) | May 13, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($9.41M) | Nov 18, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($8.29M) | Oct 29, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($8.71M) | Oct 29, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($7.82M) | Nov 13, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($7.44M) | Aug 14, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($6.14M) | May 4, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($5.82M) | Nov 3, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($6.03M) | Aug 5, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($6.36M) | May 10, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($3.91M) | Nov 8, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($3.62M) | Aug 9, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($3.96M) | May 10, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($3.96M) | Nov 9, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($3.20M) | Aug 10, 2020 |